Controlling pandemic influenza through vaccination programs

Future Virology

Volumn 4, Issue 3, 2009, Pages 271-276

  Sahni, Rajiv ^a   Mossad, Sherif B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

H5N1 vaccines; H5N1 virus; Pandemic flu; Pandemic flu preparation

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY RESPONSE; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; VIRUS DETECTION; VIRUS STRAIN; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

AVIAN INFLUENZA VIRUS;

EID: 68549093022     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.5     Document Type: Review

References (19)

1. Thompson WW, Shay DK, Weintraub E et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179-186 (2003).
2. Kilbourne ED: Influenza pandemics of the 20th Century. Emerg. Infect. Dis. 12(1), 9-14, (2006).
3. Murray CJL, Lopez AD, Chin B, Feehan D, Hill KH: Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-1920 pandemic: a quantitative analysis. Lancet 368(9554), 2211-2218 (2006).
4. Perrone LA, Tumpey TM: Reconstruction of the 1918 pandemic influenza virus: how revealing the molecular secrets of the virus responsible for the worst pandemic in recorded history can guide our response to future influenza pandemics. Infect. Disord. Drug Targets 7(4), 294-303 (2007).
5. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
6. Wood JM: Developing vaccines against pandemic influenza. Philos. Trans. R Soc. Lond. B Biol. Sci. 356(1416), 1953-1960, (2001).
7. Bresson JL, Perronne C, Launay O et al.: Safety and immunogenicity of an inactivated split-virion influenza A/Veitnam/1194/2004 (H5N1) vaccine: Phase 1 randomized trial. Lancet 367(9523), 1657-1664 (2006).
8. Lin J, Zhang J, Dong X et al.: Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomized controlled trial. Lancet 368(9540), 991-997 (2005).
9. Lipatov AS, Hoffman E, Salomon R, Yen HL, Webster RG: Cross-protectiveness and immunogenicity of influenza/duck/Singapore/3/ 97(H5) vaccines against infection with A/Vietnam/1203/04 (H5N1) virus in ferrets. J. Infect. Dis. 194, 1040-1043 (2006).
10. Suguitan Jr. AL, McAuliffe J, Mills KL et al.: Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3(9), 1541-1555 (2006).
11. Hampson AW: Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann. Acad. Med. 37(6), 510-517 (2008).
12. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF: Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum. Vaccin. 5(3), (2009) (Epub ahead of print).
13. Gao W, Soloff AC, Lu X et al.: Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80, 1959-1964 (2006).
14. Lu B, Zhou H, Ye D, Kemble G, Jin H: Improvement of influenza A/Fujian/ 411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J. Virol. 79(11), 6763-6771 (2005).
15. Subbarao K, Chen H, Swayne D et al.: Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. J. Virol. 305, 192-200 (2003).
16. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG: Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194, 159-167 (2006).
17. Tilburt JC, Mueller PS, Ottenberg AL, Poland GA, Koenig BA: Facing the challenges of influenza in healthcare settings: the ethical rationale for mandatory seasonal influenza vaccination and its implications for future pandemics. Vaccine 26S, D27-D30 (2008).
18. Christini AB, Shutt KA, Byers KE: Influenza vaccination rates and motivators among healthcare worker groups. Infect. Control Hosp. Epidemiol. 28(2), 171-177 (2007).
19. Sencer DJ, Millar JD: Reflections on the 1976 swine flu vaccination program. Emerg. Infect. Dis. 12(1), 29-33 (2006).